Eagle Pharmaceuticals (EGRX): Analyst Day Takeaway - RBC

November 14, 2016 6:56 AM EST
Get Alerts EGRX Hot Sheet
Price: $65.99 --0%

Rating Summary:
    4 Buy, 0 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 19 | Down: 13 | New: 9
Trade EGRX Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

RBC Capital analyst, Randall Stanicky, reiterated his Outperform rating on shares of Eagle Pharmaceuticals (NASDAQ: EGRX) after the analyst day and is confident in the BENDEKA base and encouraged on the potential for value creation.

Pipeline was the focus at the analyst meeting though there is still a strategic build-out taking place that should enhance value over time. No change to the Outperform rating or $93 PT.

For an analyst ratings summary and ratings history on Eagle Pharmaceuticals click here. For more ratings news on Eagle Pharmaceuticals click here.

Shares of Eagle Pharmaceuticals closed at $79.50 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

RBC Capital

Add Your Comment